Larotin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Larotin

Quick Facts

Property Description
Active ingredient Loratadine (INN)
Form Tablet, oral suspension, syrup, chewable tablet
Pharmacological class Second-generation H1-receptor antagonist
Common use (General) Relief of general allergic symptoms
Origin Synthetic compound

What Type of Medicine is Larotin and What is it Made Of?

Larotin is a pharmaceutical preparation containing the synthetic compound Loratadine as its sole active ingredient. It is classified as a second-generation antihistamine, belonging to the pharmacological class of selective H1-receptor antagonists. This design ensures the drug's action is primarily focused on counteracting histamine release in the periphery, which supports its classification as a non-sedating agent. Larotin is consistently supplied as a single-ingredient product, which allows for focused treatment of allergic symptoms without introducing the additional pharmacological action of components like decongestants. This approach to treatment is recognized by global health authorities, supporting the drug's inclusion on the World Health Organization's (WHO) List of Essential Medicines.


Larotin's Dosage Forms and Anti-Allergic Purpose

Larotin is formulated for systemic administration via the oral route and is widely available in several forms, including the solid tablet and chewable tablet, as well as liquid preparations such as an oral suspension and syrup. This range of dosage options is designed to accommodate various patient groups, including children, for whom liquid forms are often preferred. The primary purpose of Larotin is to provide effective, extended anti-allergic relief. Pharmacological studies confirm that Loratadine successfully blocks histamine activity, leading to a demonstrable decrease in typical allergic manifestations, allowing individuals to manage routine seasonal symptoms with a non-sedating formulation.

Regulatory References

  1. WHO Essential Medicines List (Loratadine entry)

What side effects are possible with Larotin?

Possible Side Effects and Safety Information

The safety profile of Larotin (loratadine) is officially documented by regulatory authorities, with adverse reactions classified by frequency based on clinical trials and post-marketing experience. The most Common adverse reactions reported in adults and adolescents include headache, somnolence (drowsiness), and fatigue. In children aged 2 to 12 years, nervousness is also frequently reported, alongside headache and fatigue.


Frequency Classification of Adverse Reactions

Adverse reactions are classified into several physiological System-Organ Classes (SOC) in regulatory documents, including Nervous system disorders, Gastrointestinal disorders, and Cardiac disorders.

Frequency Examples of Adverse Reactions (Adults)
Common Headache, Somnolence, Fatigue, Increased appetite
Uncommon Insomnia
Very Rare Hypersensitivity reactions (Angioedema, Anaphylaxis), Convulsion, Tachycardia, Abnormal hepatic function, Nausea, Dry mouth

Serious Adverse Reactions and Population-Specific Safety

Serious adverse reactions officially documented, typically classified as Very Rare, include severe hypersensitivity reactions (e.g., angioedema, anaphylaxis) and abnormal hepatic function. The official labeling provides specific safety considerations for certain patient groups.

For individuals with severe hepatic impairment, regulatory documents stipulate that a lower initial dose may be necessary due to reduced drug clearance. Furthermore, the official prescribing information notes that due to its antihistaminic effects, the medicine must be discontinued for approximately 48 hours before any diagnostic skin tests for allergies to prevent false negative results.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose of Larotin (Loratadine) primarily through its reported clinical manifestations. The most common signs documented in association with taking more than the prescribed amount include somnolence (drowsiness), tachycardia (fast heart rate), and headache.

In children, reports of overdose exceeding the recommended dosage have also involved manifestations such as extrapyramidal symptoms (involuntary movement disorders) and palpitations (irregular or rapid heartbeat sensations). Patients with pre-existing kidney or liver impairment should be aware that their condition may alter the body’s processing of the drug, which may require medical dose adjustments.

Overdose Manifestations Population-Specific Notes
Somnolence (Drowsiness) Extrapyramidal symptoms in children
Tachycardia (Fast heart rate) Palpitations in children
Headache Caution required in liver/kidney impairment

Emergency Response Statement

The regulatory guidance is uniform and explicitly states that if an overdose is suspected, urgent medical attention is required. Patients are instructed to immediately contact a Poison Control Center or emergency medical services for assistance, even if no symptoms are immediately evident. Management of overdose is considered symptomatic and supportive; official documents note that methods like dialysis are generally ineffective for removing the drug from the body.

Therapeutic Uses of Larotin

What Larotin Treats: Main Uses and Benefits

Larotin (loratadine) provides symptomatic support across key allergy-related domains, focusing on helping to ease the overall symptom load of persistent and episodic manifestations. Larotin is commonly used to temporarily relieve symptoms caused by allergies, including those associated with hay fever and hives, offering supportive therapeutic benefit that supports patients during episodes of heightened discomfort. The medication is generally used for managing symptom clusters in conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and the treatment of chronic idiopathic urticaria (hives).

Larotin is relevant for managing challenging symptoms such as frequent sneezing, runny nose (rhinorrhea), nasal and ocular itching, and the hives and pruritus (skin itching) associated with urticaria. This approach may support patients in maintaining alertness during daily functioning and contributes to improved day-to-day comfort without the fatigue that can accompany some treatments.


Quick Fact: Support for Key Allergic Symptoms

Symptom Domain Addressed Manifestations Patient Benefit
Respiratory Symptoms Sneezing, runny nose (rhinorrhea) Helps ease physical discomfort during flare-ups
Ocular Symptoms Itchy eyes, watery eyes (lacrimation) May support functional stability and comfort
Dermatologic Symptoms Hives (wheals), skin itching (pruritus) Helps improve day-to-day comfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Larotin's eligibility is strictly defined by regulatory classifications based on age, physiological status, and pre-existing medical conditions. The medicine is contraindicated and must not be used by patients with a documented hypersensitivity to loratadine, its active metabolite, or any other component in the formulation.

Use is established for adults and adolescents 12 years of age and older, and for children aged 6 years and older. For children 2 to 5 years of age, use is established for liquid formulations only. The safety and efficacy in children younger than 2 years of age have not been established, and use is generally not recommended for this age group.

Specific restrictions apply to patients with severe hepatic impairment or severe renal impairment, who are flagged for conditional use and caution. Furthermore, use is not recommended during both pregnancy and lactation as a precautionary measure, as the drug is known to be excreted into breast milk. Individuals with certain hereditary sugar intolerances (e.g., galactose intolerance) or Phenylketonuria (PKU) are restricted from using specific tablet formulations due to excipient content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Larotin has documented interactions primarily stemming from its involvement with the Cytochrome P450 3A (CYP3A) enzyme system, where it acts as a substrate and an inducer. These interactions may result in changes to the concentration of Larotin or other co-administered medicines in the body.

Interaction Classification Interacting Agents (Categories/Examples)
Contraindicated Strong CYP3A Inducers (e.g., rifampin, carbamazepine, efavirenz, phenytoin)
Avoid Concomitant Use Moderate CYP3A Inducers, Strong CYP3A Inhibitors (if feasible), CYP3A Substrates with a narrow therapeutic window

Official Interaction Statements

  • Strong CYP3A Inducers must not be used concomitantly with Larotin due to the potential for significant reduction in Larotin's systemic exposure, which may reduce its efficacy and increase the risk of hepatotoxicity. If a strong inducer was being taken, it must be discontinued for a period corresponding to three plasma half-lives of the inducer before starting Larotin therapy.
  • Strong CYP3A Inhibitors (e.g., ketoconazole, erythromycin, cimetidine) can substantially increase Larotin's concentration. If co-administration with a strong inhibitor cannot be avoided, a specific dose reduction for Larotin is required to manage the increased exposure.
  • Larotin is an inducer of CYP3A. Therefore, co-administration with sensitive CYP3A Substrates for which minimal changes in concentration may lead to serious therapeutic failure or adverse events must be avoided.

These official interaction requirements necessitate careful medication reconciliation and often require dose adjustment or strict separation from other pharmacological agents to maintain safe and effective treatment levels.

Mechanism of Action

Larotin, a tricyclic piperidine derivative, functions as a selective inverse agonist of peripheral histamine H1-receptors. Its pharmacologically active metabolite, desloratadine, also contributes to the overall effect. The drug and its metabolite exhibit limited capability to traverse the blood-brain barrier, resulting in a preferential interaction with H1-receptors located on peripheral cells, including respiratory smooth muscle, vascular endothelium, and mast cells. This selective affinity prevents the stabilization of the H1-receptor in its active conformation, thereby blocking the constitutive activity of the receptor and competitively inhibiting the binding of endogenous histamine. The resulting downstream cellular consequence is the suppression of histamine-mediated signal transduction within the targeted peripheral tissues. This intracellular inhibition limits the increase in vascular permeability and the contraction of smooth muscle, which are typically driven by H1-receptor activation. Additionally, Larotin demonstrates H1-receptor-independent anti-inflammatory properties through the inhibition of pathways such as NF-kappaB, which modulates the release of pro-inflammatory mediators from mast cells and basophils. The system-level physiological consequence is the localized attenuation of histamine-driven inflammatory and vasomotor responses.

Dosage and Administration Information

Administration Overview

Larotin is typically administered according to the specific guidance provided by a healthcare professional. The method of use depends on the formulation prescribed, which may include oral or topical applications.

General Usage Principles

Consistency is a primary factor in the effectiveness of the medication. It is generally recommended to use the product at the same time each day to maintain steady levels in the body.

  • Oral Formulations: When taken by mouth, the medication is often swallowed with a full glass of water. It may be taken with or without food, though specific gastric sensitivity may dictate a preference.
  • Topical Formulations: For external applications, the substance is applied to clean, dry skin. A thin layer is usually sufficient to cover the affected area.

Handling and Storage

Proper handling ensures the integrity of the medication. It should be kept in its original packaging until the time of use to protect it from environmental factors.

  • Store at room temperature away from direct sunlight.
  • Keep the container tightly closed when not in use.
  • Avoid exposure to excessive moisture or heat.

Missed Applications

If a scheduled application is missed, the standard approach is to resume the regular schedule as soon as it is remembered. However, if it is nearly time for the next application, the missed instance is typically bypassed to maintain the regular rhythm of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Larotin

Research for Larotin (loratadine) has been conducted across various allergic conditions, relying on an extensive body of clinical research, primarily consisting of Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-analyses. Regulators rely on this evidence when reviewing the drug's approved indications and to understand the patterns observed in clinical settings across various allergic conditions.


Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research exploring symptom patterns for Larotin during hay fever (Seasonal Allergic Rhinitis - SAR) and year-round allergies (Perennial Allergic Rhinitis - PAR) often focuses on patterns of change in physical discomfort associated with these conditions characterized by fluctuating or episodic manifestations.

Researchers mainly used short-term RCTs, comparing the use of Larotin to a placebo (an inactive substance) or to other established anti-allergy medicines. The key outcomes describing episodic or acute changes were monitored using standardized rating scales, such as the Total Symptom Score (TSS). These scales track patient-reported severity of sneezing, runny nose, nasal itching, and ocular (eye) symptoms.


Evidence for Chronic Hives (Chronic Idiopathic Urticaria)

Larotin was studied for use in conditions characterized by fluctuating or episodic manifestations such as chronic hives (Chronic Idiopathic Urticaria or CSU).

Systematic reviews and RCTs applied in research contexts involving fluctuating symptoms explored outcomes related to physical discomfort, specifically monitoring data related to pruritus (skin itching) severity scores and wheal (hive) count or size. Findings from systematic reviews suggest that the research exploring short-term symptom changes documents data points related to symptom score shifts for the active drug group. However, evidence quality varies across studies.


Research in Specific Populations and Age Groups

Research has explored how Larotin was evaluated in specific patient groups where the body's processing of medication may differ.

Studies monitored outcomes for pediatric patients across various age groups, including children as young as 2 years old, using validated symptom scores. Research describes data points related to symptom score shifts in children and adolescents, which are documented alongside those observed in adults. Specialized Pharmacokinetic (PK) studies also indicated that the body's exposure to Larotin and its metabolite may be higher in older adults and in those with significant chronic kidney or liver disease.

Frequently Asked Questions (FAQ)

Common questions about Larotin (FAQ)

Q: How quickly should I expect Larotin to start working after I take it?

Official information indicates that the anti-allergic effect of Larotin typically begins within 1 to 3 hours after a dose is taken. The peak effect may take slightly longer, but the action is generally observed to start relatively quickly based on clinical data.

Q: How long does the effect of a single dose of Larotin typically last?

Studies and official information confirm that the therapeutic effect of a single dose of Larotin lasts around 24 hours. This duration of action is consistent with a once-daily regimen.

Q: Is Larotin generally considered a sedating or non-sedating medicine?

Larotin is officially classified as a second-generation, non-sedating antihistamine. While it is designed to cause less drowsiness than older medicines, official safety information notes that some individuals may still experience mild somnolence (sleepiness) or fatigue.

Q: Can Larotin be taken if I am also taking over-the-counter (OTC) pain relievers?

Larotin is not typically contraindicated for use with common, non-sedating OTC pain relievers. However, if strong pain relievers are used, official guidance suggests caution, as they may increase the risk of drowsiness or sedation when combined with Larotin.

Q: Is Larotin used only for the conditions listed in official documents?

According to regulatory documentation, Larotin is officially indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis (hay fever) and chronic hives (urticaria). These uses are supported by clinical research evidence.

Q: Is Larotin known to interact with birth control pills?

Official safety information indicates that Larotin is not known to affect the efficacy of hormonal or non-hormonal forms of contraception. This includes common birth control pills and emergency contraception.

Q: Are there any specific supplements or herbal products that should be avoided while using Larotin?

Official guidance advises that patients inform a healthcare professional about all vitamins, herbal remedies, and supplements being used. This is a general precaution, as certain supplements may interact with or increase the potential sedating effects of this medicine.

Q: Does Larotin change the effects of alcohol?

Official warnings include a warning to exercise caution regarding alcohol consumption while using Larotin. This is because alcohol may enhance or increase the potential for side effects like drowsiness or sedation.

Q: Is there a generic version of Larotin available?

Yes, the active ingredient contained within Larotin is called loratadine. This component is widely available in a generic, non-branded form which is often sold over the counter.

Q: What should I do if Larotin does not seem to be working for me after the expected time?

Regulatory documents state that if symptoms do not improve or worsen after the expected course of use, consultation with a healthcare professional is necessary. They can provide evaluation and assist in determining the next steps.

Q: Did Larotin undergo a long-term safety review before approval?

As part of the regulatory review process, available safety data was extensively reviewed, including information on potential serious adverse events. This comprehensive review served to inform the regulatory decision regarding its acceptable safety profile for its current uses.

Q: Is Larotin suitable for use by older adults or seniors?

Regulatory information indicates that the standard adult dose is generally appropriate for elderly patients. However, those with severe kidney or liver impairment may require a specific dosage assessment by a healthcare professional, as these conditions are more common in older adults.

Q: Is it normal for the appearance (color/shape) of Larotin tablets to change between refills?

The physical appearance of a specific brand, such as the Larotin tablet, is expected to remain consistent between purchases. However, if a generic or different manufacturer's version is provided, the color, shape, and markings may differ.

Q: Can Larotin affect my ability to operate a vehicle or machinery?

Since Larotin may cause side effects like drowsiness or fatigue in some individuals, official warnings include a warning about caution. If an individual experiences tiredness or is less alert, it is advised to not engage in activities that require high mental focus, such as operating a vehicle or heavy machinery.

Q: Is Larotin the kind of medicine that can be stopped suddenly?

Larotin is an antihistamine used to manage symptoms as needed. Regulatory information does not contain specific warnings against sudden discontinuation, unlike some other classes of medication.

Q: Does Larotin lose its effectiveness over time with continuous use?

Clinical trials designed to assess long-term use have shown no evidence of subsensitivity, which is the loss of effectiveness, or tolerance developing over periods of up to 12 weeks of continuous use.

Q: Why is Larotin sometimes prescribed along with other drugs?

Larotin's active component, loratadine, is often combined with a decongestant, such as pseudoephedrine, to create combination products. These are used to treat both allergy symptoms and nasal congestion simultaneously.

Q: Can Larotin be used by people with a history of heart issues?

Based on public health guidance, Larotin at its standard dose has been generally deemed acceptable for most people with high blood pressure or other heart conditions. However, patients with a known heart issue should seek consultation from a medical professional.

Q: What is the difference between Larotin and the active metabolite drug?

Larotin contains the parent drug, loratadine, which is converted by the body into an active substance called desloratadine. Desloratadine is the primary component that carries out the anti-allergic effect and has a longer half-life than the original loratadine molecule.

Q: How does the action of Larotin differ from first-generation medicines for the same condition?

As a second-generation antihistamine, Larotin is designed to be highly selective for peripheral receptors. Due to its selective action, it is designed to minimize crossing the blood-brain barrier, thereby significantly reducing the drowsiness associated with older, first-generation antihistamines.

Q: What is the legal classification of Larotin (prescription only vs. over-the-counter)?

Larotin is one of the medications that is available both over-the-counter (OTC) at its standard strength and may also be obtained via a prescription from a healthcare professional.

Q: Can I take Larotin if I am trying to become pregnant?

Public health guidance advises that for individuals planning to become pregnant, official guidance recommends consulting a healthcare professional before starting or continuing the use of this medicine to assess whether its use is appropriate.

Q: Can Larotin affect blood pressure or heart rate?

Official safety documents indicate that, although rare, Larotin has been associated with effects on the heart rate. These can include tachycardia (a rapid heartbeat) or an irregular heart rhythm.

Q: Is Larotin non-habit-forming?

Larotin is not classified as a controlled substance. Furthermore, regulatory information does not identify this medication as having the potential to be habit-forming or cause dependence.

Q: Do official sources list specific warnings for diabetic patients using Larotin?

Official labeling does not contain a specific warning for diabetic patients using the standard tablet form of Larotin. However, patients with any pre-existing medical condition, including diabetes, it is advised to seek consultation from a healthcare professional before starting treatment.

Q: Can Larotin be used in combination with cold or flu medicines?

Caution is advised because many cold and flu products already contain an antihistamine or a sedating ingredient. To avoid excessive dosing or increased side effects like drowsiness, it is advised to avoid combining Larotin with other antihistamines.

Q: Does Larotin interact with grapefruit juice, or is that for other medicines?

While some medications must avoid grapefruit juice, there are typically no specific regulatory warnings against consuming it while taking Larotin. However, official information notes that the absorption of the medicine may be slowed down by food.

Q: What information is legally required to be provided with a Larotin prescription or purchase?

The required patient information must be provided when purchasing Larotin, such as a Medication Guide or Patient Information Leaflet (PIL). This document details the proper use, warnings, precautions, and a complete list of possible side effects.

Q: How long has Larotin been available to the public?

The active ingredient in Larotin, loratadine, was first approved for prescription use in the US in 1993. It later became available for non-prescription, over-the-counter use in the early 2000s after regulatory review.

Q: Can Larotin be crushed or split for easier swallowing?

Loratadine tablets, particularly orally disintegrating forms, are generally not designed to be crushed or split and should be swallowed whole. If a tablet is too difficult to swallow, the available liquid form is a potential alternative.

Q: Are there special warnings for using Larotin in warm or humid climates?

Regulatory storage requirements state that Larotin must be kept at a controlled room temperature, typically between 20 C and 25 C. The medicine must also be protected from excessive moisture to maintain its product integrity.

Q: Is Larotin known to cause 'rebound' symptoms if stopped?

Regulatory information does not contain warnings regarding the risk of 'rebound' symptoms—meaning an acute worsening of the original condition—or withdrawal effects after discontinuing the use of this medication.

How should Larotin be stored and disposed of?

Larotin (loratadine) must be stored under specific conditions to maintain product integrity, strictly following regulatory labeling.

Storage Requirements

Larotin tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine requires protection from excessive moisture and should be stored in its original container, tightly closed. Liquid forms are typically directed to not be frozen. All forms must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Larotin should be handled according to local requirements. The FDA advises utilizing drug take-back programs. If a program is unavailable, disposal can be done via household trash after mixing the medicine with an undesirable substance (e.g., used coffee grounds) and sealing the mixture in a bag or container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Larotin found in:

A-Z Index: